TGR-63
Targeting Brain Plaque Pathways in Alzheimer’s Disease
Designed to cross the blood–brain barrier, TGR-63 is being developed to support targeted therapeutic delivery in the brain.
What is
TGR-63?
TGR-63 is a synthetic, low molecular weight molecule, tailored designed to inhibit amyloid plaque aggregation in neuronal tissue by targeting previously unexplored binding sites. It has demonstrated brain blood barrier crossing and behavioral activity in preclinical studies.
How TGR-63 Works
TGR-63 is designed to interact with amyloid-beta peptides and may influence plaque aggregation dynamics through binding interactions. Computational studies suggest that TGR-63 may alter peptide structure and stability, supporting the formation of less aggregated states. These findings are supported by preclinical observations.
Computational Studies:
A Plausible Mode of Action
TGR-63 has shown affinity for Aβ42 peptides in computational and preclinical studies, with evidence suggesting modulation of peptide structure and aggregation behavior.
Tracing the Origins:
The Development
of TGR-63 Compound
TGR-63 was licensed from the Jawaharlal Nehru Centre for Advanced Scientific Research in India and further developed by Prof. T. Govindaraju and his research group. Their work focused on a series of naphthalene monoimide compounds, evaluating their ability to inhibit amyloid-beta aggregation, assess cytotoxicity, and support neuronal function in preclinical studies.
Pre-clinical Studies: Detailed Scientific Results
Advancing Targeted
Alzheimer’s Research
TGR-63 represents an early-stage therapeutic approach focused on modulating amyloid-beta dynamics. As part of IGC Pharma’s broader pipeline, it reflects the Company’s commitment to advancing targeted strategies for neurodegenerative diseases through a combination of scientific innovation and data-driven research.